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Abstract
Exercise-induced oxygen desaturation (EID) is prevalent in people with chronic obstructive pulmonary disease
(COPD). This article reports a sub-analysis from a randomized controlled trial (RCT) in people with COPD
and EID (COPD/EID). The primary aim, in people with COPD/ EID, was to determine the repeatability of the
distance and time walked in the incremental shuttle walk test (ISWT) and endurance shuttle walk test (ESWT),
respectively. A secondary aim was to determine whether any participant characteristics predicted those who
did not demonstrate improvements on a repeat ISWT or ESWT. Participants with nadir oxygen saturation
(SpO2) < 90% on the 6-minute walk test were recruited to the RCT. Two ISWTs and two ESWTs were then
performed as part of the baseline assessments, and participants were included in this sub-analysis if their nadir
SpO2 was <90% during the better of two ISWTs. Repeatability of the tests was analysed using Bland–Altman
plots and paired t-tests. Participant characteristics of age, lung function, level of nadir SpO2 and end-test
dyspnoea were used to predict those who were not likely to demonstrate improvements on a repeat test
using receiver operating curves. Eighty-seven participants (mean age (standard deviation, SD) 70 (7) years;
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forced expiratory volume in one second (FEV1) 47 (17)% predicted) were included. The mean differences
(coefficient of repeatability) for the ISWTs and ESWTs were 9 m (55 m) and 19 seconds (142 seconds)
respectively (p < 0.05). No participant characteristic predicted the absence of improvement on the second
ISWT (area under the curve (AUC) ranged from 0.49 to 0.58, all p > 0.2) or the second ESWT (AUC ranged
from 0.43 to 0.52, all p > 0.3). Although repeating the tests showed only small improvements in distance
(ISWT) and time (ESWT) walked in people with COPD/EID, the variability was large making definite
conclusions about test repeatability in these individuals difficult.
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Introduction
Field walk tests such as the six-minute walk test
(6MWT), incremental shuttle walk test (ISWT) and
endurance shuttle walk test (ESWT) are commonly
used in the assessment of exercise tolerance in people
with chronic obstructive pulmonary disease (COPD).
Exercise-induced oxygen desaturation (EID) during
field walk tests is common in people with COPD. A
few studies1–3 showed that between 47% and 74% of
patients referred to pulmonary rehabilitation demon-
strated a nadir oxygen saturation (SpO2) during
6MWT of <90%. Although the definition of EID that
is clinically important for people with COPD has not
been determined, it is often reported as a decline in
SpO2 of 4% or >4% to <90% during a 6MWT.1,2
The reliability of field walk tests, such as the
ISWT and ESWT, is well established.4,5 The recent
technical standards for field walk tests for people with
stable COPD4 recommended the need to account for
improvements that result from test familiarization
during the ISWT by recording the better result of two
tests. Whether people improve with test familiariza-
tion on the ESWT was less clear.4 The repeatability of
the ISWT and ESWT has not been investigated in the
subgroup of people with COPD who demonstrate EID
(COPD/EID). Given that EID in people with COPD is
common,1,2 and field walk tests are regularly used as
part of exercise assessment in rehabilitation programs
and to determine the need for ambulatory oxygen
therapy in this group, a better understanding of the
need to repeat these field walk tests in this subgroup
is warranted. There is a possibility that the learning
effect in performance of the ISWT and ESWT is not
as pronounced in this subgroup as they may experi-
ence primarily symptom limitation associated with
EID, such as dyspnoea and/or fatigue, to end the test
rather than test termination being associated with lack
of familiarization. If the learning effect is not as pro-
nounced in those with COPD/EID, there could be
resource implications and repeating the walk tests may
not be required. It would also be useful for clinicians
to know if any patient characteristics could predict
those who are not likely to demonstrate improvements
on a repeat test in this subgroup; however, this has not
been previously determined.
This article reports a sub-analysis from a larger
randomized controlled trial (RCT) where people with
COPD/EID were recruited. The primary aim of this
sub-analysis was to determine the repeatability of the
distance and time walked in the ISWT and ESWT,
respectively. A secondary aim was to determine
whether any participant characteristics predicted
those who did not demonstrate improvements on a
repeat ISWT or ESWT.
Methods
Participants
Measurements collected during the baseline assess-
ment conducted for a multi-centre RCT were used
to address the aims in this sub-analysis. People with
COPD were recruited from referrals to pulmonary
rehabilitation programs at seven Australian sites
(Royal Prince Alfred Hospital, New South Wales
(NSW); Concord Repatriation General Hospital,
NSW; Liverpool Hospital, NSW; Austin Health
and Alfred Health, Victoria; Sir Charles Gardiner
Hospital, Western Australia; Prince Charles Hospital,
Queensland) and were screened using a 6MWT to
ensure evidence of EID (i.e. SpO2 < 90% during the
6MWT performed on room air). The additional inclu-
sion and exclusion criteria for the RCT have been
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reported previously.6 For inclusion in these sub-
analyses, participants were required to also demon-
strate EID during the ISWT (one of two) in which the
greater distance was achieved (i.e. SpO2 < 90%). This
study was performed with approval from the Ethics
Committee of all participating sites and all partici-
pants provided written informed consent. The trial
was registered with Australian New Zealand Clinical
Trials Registry: ACTRN12612000395831.
Measurements
Participants’ age, height, weight, spirometry, lung
volumes and diffusing capacity were measured at
baseline according to standard protocols.7
The ISWT and ESWT were performed according to
the published protocols.8,9 Each participant performed
two ISWTs on the same day and two ESWTS on
another day, within 7 days of the initial ISWTs. Parti-
cipants rested for at least 30 minutes between tests or
until SpO2, Borg dyspnoea score and heart rate
returned to resting levels. Heart rate and SpO2 were
continuously monitored for all tests using a portable
oximeter (RAD-5v Masimo Corp., Irvine, California,
USA) and recorded each minute. Additionally,
dyspnoea and rate of perceived exertion (RPE) were
measured at the beginning and end of all tests using a
modified Borg 0–10 scale.10,11 The initial speed for the
ESWT was calculated as 85% of the peak speed that
participants achieved on the ISWT.12 As the ESWT
was the primary outcome for the RCT, during baseline
testing, if the initial ESWT test time exceeded 8 min-
utes and the participant showed minimum signs of
exertion or breathlessness, the test was terminated and
the speed was increased to the next level for the repeat
test. However, for the sub-analyses related to ESWT,
only data from those participants who performed both
baseline tests at the same speed were included.
Power
The sample available for these analyses (n ¼ 66)
provided adequate power (1  b ¼ 0.8, a ¼ 0.05)
to detect a within-participant mean difference in per-
formance on the ISWT or ESWT that was equivalent
to a moderate effect size or greater (i.e. an effect size
0.35 of a SD from the mean). This sample size
was also sufficient to detect an area under the recei-
ver operating characteristic (ROC) curve of 0.7,
for predictors used to separate those who did versus
did not improve their performance on the second
ISWT or ESWT.
Statistical analysis
Data were analysed using SPSS version 22 (SPSS
Inc., Chicago, Illinois, USA). Repeatability of the
walk tests was analysed using the methods of Bland
and Altman.13 For the ISWT and ESWT repeatabil-
ity, the mean difference was calculated between the
first and second tests, and the coefficient of repeat-
ability (CR) was calculated as the product of 1.96 and
the SD of the mean difference. The CR provides the
limits of agreement around the mean difference
within which 95% of the mean difference values will
be included. For both the ISWT and ESWT, paired
t-tests were used to determine whether the measures
(distance, time, cardiorespiratory responses and
symptom scores) differed significantly between the
first and second tests. ROC curves were used to
assess whether there was an optimal cut-point value
in the continuous variables of interest (i.e. age,
FEV1% predicted, end-test dyspnoea, end-test RPE
and nadir SpO2 during the first ISWT or ESWT) that
would separate those participants who did versus did
not improve on their second ISWT or ESWT.
Table 1. Characteristics of participants involved in the






Age, yr 70 (7) 70 (8)
Gender, females (n, %) 37 (43%) 30 (46%)
Height, cm 167 (11) 167 (11)
Weight, kg 78 (19) 77 (18)
Body mass index, kg/m2 28 (7) 27 (6)
Smoking history, pack years 45 (23) 45 (25)
FEV1, L 1.2 (0.4) 1.2 (0.4)
FEV1, % predicted 47 (17) 46 (17)
FVC, L 3.0 (0.9) 2.9 (0.9)
FVC, % predicted 84 (18) 85 (19)
FEV1/FVC, % 42 (12) 42 (12)
DLCO, mL/min/mmHg 12 (14) 13 (16)
DLCO, % predicted 47 (15) 47 (15)
Best ISWT, m 284 (125) 280 (113)
Best ESWT, s 311 (120) 311 (120)
SD: standard deviation; n: number; yr: years; kg: kilograms; kg/m2:
kilograms per metres squared; FEV1: forced expiratory volume in
one second; % pred: percent predicted; FVC: forced vital capacity;
DLCO: diffusion capacity of the lung for carbon monoxide; ISWT:
incremental shuttle walk test; ESWT: endurance shuttle walk test;
mL/min/mmHg: millilitres per minute per millimetres of mercury;
m: metres; s: seconds.
aData presented as mean (SD).
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Participants were grouped as ‘no improvement on the
second test’ if there was no improvement or a dete-
rioration between the first and second tests or ‘did
improve on a second test’ if there was any improve-
ment >0 m between the first and second tests. w2 tests
were used to assess whether gender was associated
with group membership. For all analyses, p values
<0.05 were considered significant.
Results
Eighty-seven participants met the inclusion criteria
for the study. Their characteristics are presented in
Table 1. Eighty-four participants desaturated on both
ISWTs, with the three participants who only desatu-
rated on one test having a nadir SpO2 of 91% on the
other test. For the ESWT, 66 of the 87 participants had
data on two tests at the same walking speed and their
characteristics are also presented in Table 1. Of the
66 participants, 61 participants (92%) demonstrated a
nadir SpO2 < 90% on at least one of the ESWTs.
The repeatability of performance and cardiore-
spiratory responses for the repeat ISWTs and
ESWTs are presented in Table 2. For the ISWT
and ESWT, the mean differences between the first
and second tests (CR) were 9 m (55 m) and 19
seconds (142 seconds), respectively (both p < 0.05).
Bland–Altman plots are presented in Figure 1. The
end-test cardiorespiratory responses were similar
for the two ISWTs and the two ESWTs except for
end-test dyspnoea score which was statistically
higher on the second test for both the ISWT and
ESWT (Table 2).
Table 3 presents the ROC curves generated for
variables that may have predicted participants who
improved versus did not improve on their second
ISWT or ESWT. No participant characteristic pre-
dicted which participants did not demonstrate an
improvement on the second test for the ISWT (area
under the curve (AUC) ranged from 0.49 to 0.59, all
p > 0.1) or for the ESWT (AUC ranged from 0.43 to
0.52, all p > 0.3). Notably, gender was also not
Table 2. Exercise performance, cardiorespiratory and symptoms responses during ISWT and ESWT.a
ISWT (n ¼ 87) ESWT (n ¼ 66)
Test 1 Test 2
Mean
difference (SD)
CR Test 1 Test 2
Mean
difference (SD)
CR95% CI 95% CI
Distance (m) 270 (122) 278 (124) 9 (28) 55 307 (157) 328 (171) 22 (78) 153
3 to 15b 2 to 41b
Time (seconds) – – 281 (110) 300 (124) 19 (72) 142
1 to 37b
SpO2, % At rest 94 (2) 94 (2) 0.2 (1.4) 3 94 (2) 94 (3) 0.2 (3.1) 6
1 to 0 1 to 1
End test 85 (3) 85 (3) 0.6 (3.5) 7 84 (4) 84 (4) 0.4 (3.3) 7
1 to 0 1 to 0
Nadir 85 (3) 85 (3) 0.4 (3.1) 6 83 (5) 84 (4) 0.2 (3.4) 7
1 to 0 1 to 1
HR, bpm At rest 86 (15) 87 (14) 0.9 (8) 15 87 (14) 87 (14) 0.6 (8) 16
1 to 3 3 to 1
End test 115 (16) 115 (18) 0.3 (10) 20 116 (16) 113 (19) 3 (17) 34
3 to 2 7 to 1
Dyspnoea At rest 1 (1) 1 (1) 0.0 1 1 (1) 1 (1) 0.1 1
0.1 to 0.1 0.2 to 0.0
Dyspnoea End test 5 (2) 5 (2) 0.3 (1.3) 3 6 (2) 6 (2) 0.3 (1.0) 2
0.0 to 0.6b 0.0 to 0.5b
RPE End test 4 (2) 4 (2) 0.02 (1.0) 2 5 (3) 5 (3) 0.1 (1.4) 3
0.2 to 0.2 0.2 to 0.5
bpm: beats per minute; CI: confidence interval; CR: coefficient of repeatability; ESWT: endurance shuttle walk test; HR: heart rate;
ISWT: incremental shuttle walk test; RPE: rate of perceived exertion; SD: standard deviation; SpO2: oxygen saturation.
aData presented for test 1 and test 2 presented as mean (SD).
bSignificantly different between the first and second ISWT or ESWT (p < 0.05).
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associated with those who did not need a second test
for the ISWT (p ¼ 0.1) or ESWT (p ¼ 0.2).
Discussion
To our knowledge, this is the first study to investigate
the repeatability of the ISWT andESWT in peoplewith
COPD/EID. The main findings of this study were that
the distance walked in the ISWT and the duration of
walking in the ESWT showed only small differences
between the first and second tests. In addition, therewas
a statistically significant difference with the end-test
dyspnoea score for the ISWT and ESWT with repeat
testing, but the difference was only small and not clini-
cally relevant.14 While these main findings might sug-
gest that repeat tests are not needed for a group of
peoplewith COPD/EID, the coefficient of repeatability
was wide, indicating variability in individual
responses. We were not able to identify any participant
characteristics that could predict those who did not
demonstrate improvement on a second test.
This study has shown that people with COPD/EID
walk significantly further and longer on a second test
for the ISWT and ESWT, respectively, but the overall
mean difference was small (ISWT ¼ 9 m; ESWT ¼
19 seconds). Interestingly, this amount of difference
was lower than that reported for people with COPD
without specified EID (20–25 m on the ISWT and
26 seconds on the ESWT).4 No study has previously
reported on repeatability of the ISWT and ESWT in a
large group of people with COPD/EID. One study
discussed a subgroup analysis involving people with
COPD/EID when reporting the repeatability of the
ISWT in people with COPD and showed a difference
of 26.5 m between repeat ISWTs in this subgroup.15
The details provided about the participants in
this subgroup analysis were inadequate to enable
comparison with the current study.
When reviewing the Bland–Altman plots for both
the ISWT and ESWT, the mean differences were
small but the upper bounds of the CR were high being
64 m for the ISWT and 161 seconds for the ESWT
indicating that some participants had large differences
between repeat tests. The proportion of the sample who
demonstrated an improvement in ISWT and ESWT on
repeat testing was 49% and 53%, respectively (Figure
1(a) and (b)). In stable COPD, it has been suggested
that two tests are required for the ISWT in order to
account for the learning effect but that one test may
be sufficient for the ESWT.4 As approximately 50% of
the group improved on either the ISWT or ESWT with
repeat testing, it seems that repeat testing is needed in
order to adequately interpret changes in these measures
following an intervention.
Understanding whether there are any participant
characteristics that can be used to predict who does
not demonstrate an improvement on a second ISWT
or ESWT would be useful to guide clinicians in their
decisions about who requires repeat testing. Obvi-
ously, this issue has resource and time implications
for assessment clinics or rehabilitation programs.
The results of the ROCs in this study for age, FEV1
(%predicted), end-test dyspnoea, end-test RPE
and nadir SpO2 during the first ISWT or ESWT indi-
cated AUC values were <0.6 and not significant,
suggesting that no participant characteristic was able
to predict lack of improvement on a second test.
Figure 1. Bland–Altman plots (a) difference in distance
walked in ISWT and (b) difference in time walked in ESWT.
Mean difference shown as solid line, 95% limits of agree-
ment as dashed lines (1.96  SD). ISWT: incremental
shuttle walk test; ESWT: endurance shuttle walk test;
SD: standard deviation.
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One of the limitations of this study was that results
may have been affected by order bias, as testing
sequence was standardized rather than random. In
addition, this study has only demonstrated the size
of the learning effect in the ISWT and ESWT before
exercise training in people with COPD/EID. The
learning effect in ISWT and ESWT after exercise
training in people with COPD/EID remains unknown.
In this study, all testing took place on room air so
conclusions can only be made about repeat testing
on room air. Given that tests such as the ESWT may
also be used to determine response to ambulatory
oxygen in people with COPD/EID, in future studies,
it would be important to identify whether repeat
testing is needed under these conditions.
Conclusion
In a group of people with moderate to severe COPD
with EID, repeating the ISWT and the ESWT resulted
in only small improvements in walk distance and
walk time, respectively. However, the wide CR
coupled with the inability to use participant charac-
teristics to predict those who did not improve on
repeat testing make conclusions on whether repeat
testing should be performed for any given individual
with COPD/EID difficult.
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